Orvasta (Atorvastatin)

Atorvastatin, the active ingredient in Orvasta, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels in adults at risk for cardiovascular disease. GNH USA supplies Orvasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Orvasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orvasta is a lipid‑lowering agent that acts on the cholesterol synthesis pathway. It is indicated for: - Primary hypercholesterolaemia: reduces LDL‑C and total cholesterol levels. - Mixed dyslipidaemia: lowers triglycerides and raises HDL‑C modestly. - Primary prevention of cardiovascular events: helps reduce the risk of myocardial infarction, stroke and related vascular events in high‑risk patients.

Adverse reactions to Orvasta vary in frequency and severity.

Common Side Effects: - Myalgia or muscle aches. - Elevated liver enzymes (ALT/AST). - Gastrointestinal discomfort such as nausea or abdominal pain. - Headache. - Dizziness.

Serious or Rare Side Effects: - Rhabdomyolysis or severe muscle breakdown. - Acute hepatic failure. - Severe allergic reactions including angioedema. - New‑onset diabetes mellitus. - Persistent unexplained fatigue.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor relevant parameters. - Liver function: obtain baseline ALT/AST and repeat periodically. - Muscle health: evaluate for myopathy symptoms, especially if combined with interacting drugs. - Renal impairment: adjust monitoring in patients with severe kidney disease. - Pregnancy and lactation: avoid use unless clearly indicated, as safety is not established. - Drug interactions: review concomitant medications for potential statin interactions. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Atorvastatin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). - Gemfibrozil and other fibrates that increase risk of myopathy. - Cyclosporine and certain antivirals (e.g., boce-boi.

Moderate Interaction ( Monitor Closely): - Antacids containing aluminum or magnesium. - Warfarin, requiring INR monitoring. - Niacin, which may increase risk of liver enzyme elevation. - Digoxin, as statins can modestly raise serum levels. - St. St